This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

July 8, 2025

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO
	(Code No. 4576)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Announcement regarding the commencement of joint research with Chordia Therapeutics Inc.

We are pleased to announce that we have entered into an agreement with Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; CEO & Representative Director: Hiroshi Miyake; hereinafter “Chordia”) for joint research (the “Joint Research”) aimed at the development of therapeutic agents for ophthalmic diseases.

Under this Joint Research, we have agreed to conduct a joint study using a specific compound (hereinafter referred to as the “Compound”) from Chordia’s oncology pipeline, which is currently in the discovery research stage and exhibits kinase inhibitory activity, to develop therapeutic agents for ophthalmic diseases. Our company and Chordia will collaborate on research aimed at developing therapeutic agents for ophthalmic diseases, leveraging each party's technologies, resources, and pharmaceutical R&D expertise.
Concerning the division of roles in this Joint Research, Chordia will be responsible for providing know-how and research materials related to the Compound. At the same time, our company will conduct efficacy and pharmacological studies by leveraging our evaluation technologies in the ophthalmology field to assess the potential of the Compound as a therapeutic agent for ophthalmic diseases. Upon completion of this joint research, we plan to discuss the next phase of collaboration.

We are focusing on the ophthalmology field and are engaged in drug discovery activities aimed at creating new drug candidates.
Chordia is also engaged in the discovery of small-molecule compounds, similar to our company, but possesses a different class of compounds. This will enable us to utilize our expertise in ophthalmic diseases to the fullest.

This matter will not result in any revisions to the earnings forecast for the fiscal year ending December 2025. However, it will contribute to the expansion of our ophthalmology pipeline over the medium to long term.

End

About Chordia Therapeutics Inc.

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research of several clinical and preclinical assets, including MALT1 inhibitor CTX-177, CDK12 inhibitor CTX-439 and GCN2 inhibitors. For more information, please contact our website https://www.chordiatherapeutics.com/en/.

About D.Western Therapeutics Institute

D.Western Therapeutics Institute is a biotech company with the mission of "Innovative New Drugs to the World from Japan," aiming to provide patients with more effective medicines as quickly as possible. DWTI specialize in the creation of kinase inhibitors (low molecular weight compounds) and have own proprietary drugs on the market. Currently, focusing on the ophthalmic field and are working on regenerative medicine products to contribute to providing the best possible treatment for patients.
For more details, please visit DWTI's website at https://dwti.co.jp/english/.